Step 1 of A Two-step Trial to Evaluate the Effectiveness and Safety of Remimazolam Besylate for Sedation in ICU Patients

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2022
This is a Phase II, dose-escalation clinical trial conducted in mechanically ventilated patients receiving sedation no longer than 24 hours. The efficacy, safety, and pharmacokinetics of remimazolam besylate were evaluated using a randomized, single-blind design.
Epistemonikos ID: 676021dc387494567798cc3d0916f17f24dad804
First added on: May 15, 2024